Epigenomics AG issues new shares by way of private placement

Epigenomics AG  / Key word(s): Capital Increase

16.11.2016 15:13

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Publication of Inside Information according to Article 17 MAR

Epigenomics AG issues new shares by way of private placement

Not for distribution in the United States of America

Berlin, Germany, November 16, 2016 - Epigenomics AG, Berlin, Germany (Prime
Standard Segment, Frankfurt: ECX,  ISIN: DE0000A11QW50), announces that the
Company is raising EUR 2.1 million of gross proceeds in a share capital
increase by way of private placement.

The Executive Board of Epigenomics AG, with approval of the Supervisory
Board, has today resolved on the increase of the Company's share capital in
the amount of EUR 474,800.00 by issuing 474,800 new registered shares of
the Company from the Authorized Capital 2016/I against contribution in
cash. The issue price has been set at EUR 4.52 per share.  The new shares
will carry dividend rights from January 1, 2016.

The capital increase was fully subscribed by Cathay Fortune International
Company Limited, an institutional investor from China.

Following the registration of the capital increase with the commercial
register ("Handelsregister") - and subject to the registration of the
capital increase resolved on November 7, 2016 - the subscribed capital of
Epigenomics AG will increase to EUR 22,054,005.00. The admission of the new
shares to the regulated market (prime standard) of the Frankfurt Stock
Exchange is expected during December 2016. The technical implementation of
the capital increase is conducted by Bankhaus Neelmeyer, Bremen, Germany.

Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to expand the U.S commercialization capacities
for its lead product Epi proColon.

-End of publication -

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the "Shares") have not been registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act") and may not be
offered or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares will not
be registered under the Securities Act.

Contact Epigenomics AG

Peter Vogt
Vice President Corporate Communications & Investor Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386
ir@epigenomics.com
Home



---------------------------------------------------------------------------

Information and Explanation of the Issuer to this News:

Greg Hamilton, Chief Executive Officer of Epigenomics AG, commented: ''We
are delighted to add Cathay Fortune International Company as a significant
investor. Cathay Fortune's diverse and knowledgeable resources are
representative of the growing interest of major investors from China as
expressed in the recent capital measures. With a combined ownership of more
than 15%, BioChain, SummitView Capital and Cathay Fortune have become the
top three shareholders of Epigenomics, sharing our belief in the great
commercial potential of our liquid biopsy platform worldwide.'

16.11.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Epigenomics AG
              Geneststraße 5
              10829 Berlin
              Germany
Phone:        +49 30 24345-0
Fax:          +49 30 24345-555
E-mail:       ir@epigenomics.com
Internet:     www.epigenomics.com
ISIN:         DE000A11QW50
WKN:          A11QW5
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart,
              Tradegate Exchange
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------